Promising agents for treating Alzheimer's disease

American Journal of Health-System Pharmacy

Volumn 55, Issue 21 SUPPL., 1998, Pages

  Simonson, William ^a  

^a Center for Health Information   (United States)

Author keywords

Alzheimer's disease; Anti inflammatory agents; Antioxidants; Clinical studies; Combined therapy; Drug comparisons; Drugs; EGb 761; Estrogens; Ginkgo biloba; Investigational; Mechanism of action; Selegiline; Toxicity; Vitamin E; Vitamins

Indexed keywords

ANTIINFLAMMATORY AGENT; ANTIOXIDANT; ASCORBIC ACID; CHOLINESTERASE INHIBITOR; DONEPEZIL; ESTROGEN; GALANTAMINE; GINKGO BILOBA EXTRACT; HEPTYLSTIGMINE TARTRATE; METRIFONATE; MONOAMINE OXIDASE INHIBITOR; NERVE GROWTH FACTOR; NONSTEROID ANTIINFLAMMATORY AGENT; PHYSOSTIGMINE; RISPERIDONE; RIVASTIGMINE; SELEGILINE; SEROTONIN UPTAKE INHIBITOR; TACRINE; TRAZODONE; UNCLASSIFIED DRUG; XANOMELINE;

ALZHEIMER DISEASE; ANTIINFLAMMATORY ACTIVITY; CONFERENCE PAPER; DRUG EFFECT; DRUG EFFICACY; DRUG MECHANISM; DRUG SAFETY; ENZYME INHIBITION; ESTROGEN THERAPY; HUMAN; PATIENT COMPLIANCE; PRIORITY JOURNAL;

EID: 0032211787     PISSN: 10792082     EISSN: None     Source Type: Journal    
DOI: 10.1093/ajhp/55.suppl_2.s11     Document Type: Conference Paper

References (33)

1. Corey-Bloom J, Galasko D. Adjunctive therapy in patients with Alzheimer's disease: a practical approach. Drugs Aging. 1995; 7:79-87.
2. Cummings JL, Kaufer D. Neuropsychiatric aspects of Alzheimer's disease: the cholinergic hypothesis revisited. Neurology. 1996; 47:876-83.
3. Geldmacher DS, Whitehouse PJ. Evaluation of dementia. N Engl J Med. 1996; 335:330-5.
4. Whitehouse PJ, Price DL, Clark AW et al. Alzheimer's disease: evidence for selective loss of cholinergic neurons in the nucleus basalis. Ann Neurol. 1981; 10:122-6.
5. Whitehouse PJ, Price DL, Struble RG et al. Alzheimer's disease and senile dementia: loss of neurons in the basal forebrain. Science. 1982; 215:1237-9.
6. Perry EK, Tomlinson BE, Blessed G et al. Correlation of cholinergic abnormalities with senile plaques and mental test scores in senile dementia. Br Med J. 1978; 2:1457-9.
7. Morris JC, Cyrus PA, Orazem J et al. Metrifonate benefits cognitive, behavioral, and global function in patients with Alzheimer's disease. Neurology. 1998; 50:1222-30.
8. Jann MW. Pharmacology and clinical efficacy of cholinesterase inhibitors. Am J Health-Syst Pharm. 1998; 55(suppl 2):S22-5.
9. Eglen RM, Watson N. Selective muscarinic receptor agonists and antagonists. Pharmacol Toxicol. 1996; 78:59-68.
10. Levey AI, Kitt CA, Simonds WF et al. Identification and localization of muscarinic acetylcholine receptor proteins in brain with subtype-specific antibodies. J Neurosci. 1991; 11:3218-26.
11. Flynn DD, Ferrari-DiLeo G, Mash DC et al. Differential regulation of molecular subtypes of muscarinic receptors in Alzheimer's disease. J Neurochem. 1995; 64:1888-91.
12. Bodick NC, Offen WW, Levey AI et al. Effects of xanomeline, a selective muscarinic receptor agonist, on cognitive function and behavioral symptoms in Alzheimer disease. Arch Neurol. 1997; 54:465-73.
13. Sramek JJ, Sedman AJ, Reece PA et al. The safety and tolerability of CI-979 in patients with Alzheimer's disease. Life Sci. 1995; 57:503-10.
14. Sramek JJ, Hurley DJ, Wardle TS et al. Safety and tolerability of xanomeline tartrate in patients with Alzheimer's disease. J Clin Pharmacol. 1995; 35:800-6.
15. Meier-Ruge W, Bertoni-Freddari C, Iwangoff P. Changes in brain glucose metabolism as a key to the pathogenesis of Alzheimer's disease. Gerontology. 1994; 40:246-52.
16. Aisen PS, Davis KL. The search for disease-modifying treatment for Alzheimer's disease. Neurology. 1997; 48(suppl 6):S35-41.
17. Lerner A, Koss E, Debanne S et al. Smoking and oestrogen-replacement therapy as protective factors for Alzheimer's disease. Lancet. 1997; 349:403-4. Letter.
18. Smith AL, Whitehouse PJ. Progression in the management of Alzheimer's disease. Hosp Pract. 1998; 33:151-4.
19. Wagstaff AJ, McTavish D. Tacrine: a review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in Alzheimer's disease. Drugs Aging. 1994; 4:510-40.
20. Cummings JL, Cyrus PA, Bieber F et al. Metrifonate treatment of the cognitive deficits of Alzheimer's disease. Neurology. 1998; 50:1214-21.
21. Hinz VC, Grewig S, Schmidt BH. Metrifonate induces cholinesterase inhibition exclusively via slow release of dichlorvos. Neurochem Res. 1996; 21:331-7.
22. Knopman D, Schneider L, Davis K et al. Long-term tacrine (Cognex) treatment: effects on nursing home placement and mortality. Neurology. 1996; 47:166-77.
23. Rogers SL, Farlow MR, Doody RS et al. A 24-week, double-blind, placebo-controlled trial of donepezil in patients with Alzheimer's disease. Neurology. 1998; 50:136-45.
24. Sano M, Ernesto C, Thomas RG et al. A controlled trial of selegiline, alpha-tocopherol, or both as treatment for Alzheimer's disease. N Engl J Med. 1997; 336:1216-22.
25. Freedman M, Rewilak D, Xerri T et al. L-deprenyl in Alzheimer's disease: cognitive and behavioral effects. Neurology. 1998; 50:660-8.
26. Kawas C, Resnick S, Morrison A et al. A prospective study of estrogen replacement therapy and the risk of developing Alzheimer's disease: the Baltimore Longitudinal Study of Aging. Neurology. 1997; 48:1517-21.
27. Jenkinson ML, Bliss MR, Brain AT et al. Rheumatoid arthritis and senile dementia of the Alzheimer's type. Br J Rheumatol. 1989; 28:86-8. Letter.
28. Rich JB, Rasmusson DX, Folstein MF et al. Nonsteroidal anti-inflammatory drugs in Alzheimer's disease. Neurology. 1995; 45:51-5.
29. Breitner JCS, Gau BA, Welsh KA et al. Inverse association of anti-inflammatory treatments and Alzheimer's disease: initial results of a co-twin control study. Neurology. 1994; 44:227-32.
30. Stewart WF, Kawas C, Corrada M et al. Risk of Alzheimer's disease and duration of NSAID use. Neurology. 1997; 48:626-32.
31. Le Bars PL, Katz MM, Berman N et al., for the North American EGb Study Group. A placebo-controlled, double-blind, randomized trial of an extract of Ginkgo biloba for dementia. JAMA. 1997; 278:1327-32.
32. Schneider LS. New therapeutic approaches to Alzheimer's disease. J Clin Psychiatry. 1996; 57(suppl 14):30-6.
33. Schneider LS, Farlow MR, Henderson VW et al. Effects of estrogen replacement therapy on response to tacrine in patients with Alzheimer's disease. Neurology. 1996; 46:1580-4.